Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma.
Frederico Omar Gleber-NettoDavid NeskeyAna Flávia de Mattos CostaPranav KatariaXiayu RaoJing WangLuiz Paulo KowalskiCurtis R PickeringEmmanuel Dias-NetoJeffrey N MyersPublished in: Cancer (2020)
High-risk TP53 mutations are associated with an increased chance of detecting ENE in patients with advanced OSCC. Because ENE is 1 of the major factors considered for OSCC patient management, TP53 mutation status may represent a potential ancillary biomarker for treatment decisions regarding postoperative adjuvant therapy.